Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: Different boosting intervals and implications for efficacy trials

PLoS ONE

Volumn 2, Issue 10, 2007, Pages

  Pathan, Ansar A ^a   Sander, Clare R ^a   Fletcher, Helen A ^a   Poulton, Ian ^a   Alder, Nicola C ^b   Beveridge, Natalie E R ^a   Whelan, Kathryn T ^a   Hill, Adrian V S ^a   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MODIFIED VACCINIA ANKARA EXPRESSING ANTIGEN 85A; UNCLASSIFIED DRUG; VIRUS ANTIGEN; BACTERIAL ANTIGEN; RECOMBINANT PROTEIN;

ANTIGEN EXPRESSION; ARTHRALGIA; ARTICLE; AXILLARY LYMPH NODE; BIOCHEMISTRY; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHEMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; MONOTHERAPY; MYALGIA; MYCOBACTERIOSIS; NAUSEA; OBSERVATIONAL STUDY; PAIN; PRURITUS; SIDE EFFECT; SKIN INDURATION; SYNCOPE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; VACCINATION; VACCINIA; VACCINIA ANKARA; VIRUS RECOMBINANT; ADULT; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; MALE; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; TUBERCULIN TEST; VACCINIA VIRUS;

ADULT; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; BCG VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME; TUBERCULIN TEST; VACCINATION; VACCINIA VIRUS;

EID: 41849129820     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001052     Document Type: Article

References (21)

1. Partnership ST (2006) The Global Plan to stop TB 2006-2015.
2. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature [see comments]. Jama 271(9): 698-702.
3. Rodrigues LC, Diwan VK, Wheeler JG (1993) Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22(6): 1154-8.
4. Trunz BB, Fine P, Dye C (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness Lancet 367(9517): 1173-80.
5. Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, et al. (2005) Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366(9493): 1290-5.
6. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93-129.
7. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178(6): 2249-54.
8. Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, Baretto R, et al. (2004) Clinical features of dominant and recessive interferon gamma receptor I deficiencies. Lancet 364(9451): 2113-21.
9. Kaufmann SH, McMichael AJ (2005) Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 11(4 Suppl): S33-44.
10. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P (2000) Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 30(12): 3689-98.
11. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, et al. (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4(4): 397-402.
12. Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, et al. (1999) Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 73(9): 7524-32.
13. McShane H, Brookes R, Gilbert SC, Hill AV (2001) Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 69(2): 681-6.
14. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10(11): 1240-4.
15. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV (2002) Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun 70(3): 1623-6.
16. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, et al. (2006) A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immum 74(10): 5933-42.
17. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, et al. (2006) Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime bo healthy HIV-1-uninfected volunteers. Vaccine 24(4): 417-25.
18. Weir RE, Fine PE, Nazareth B, Floyd S, Black GF, King E, et al. (2003) Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria. Clin Exp Immunol 134(2): 285-94.
19. Gorak-Stolinska P, Weir RE, Floyd S, Lalor MK, Stenson S, Branson K, et al. (2006) Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine. Vaccine 24(29-30): 5726-33.
20. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G (2005) Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 365(9454): 130-4.
21. Should HIV vaccines be mandatory for all adolescents? Lancet 2006; 368(9543): 1212.